Stockreport

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Sana Biotechnology, Inc.  (SANA) 
PDF Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology [Read more]